PLOS ONE RESEARCH ARTICLE A comprehensive SARS-CoV-2 genomic analysis identifies potential targets for drug repurposing 1☯ 1☯ 2,3 Nithishwer Mouroug Anand , Devang Haresh Liya , Arpit Kumar PradhanID *, Nitish Tayal4, Abhinav Bansal5, Sainitin Donakonda6, Ashwin Kumar Jainarayanan7,8* 1 Department of Physical Sciences, Indian Institute of Science Education and Research, Mohali, India, 2 Graduate School of Systemic Neuroscience, Ludwig Maximilian University of Munich, Munich, Germany, 3 Klinikum rechts der Isar, Technische UniversitaÈt MuÈnchen, MuÈnchen, Germany, 4 Department of Biological Sciences, Indian Institute of Science Education and Research, Mohali, India, 5 Department of Chemical a1111111111 Sciences, Indian Institute of Science Education and Research, Mohali, India, 6 Institute of Molecular a1111111111 Immunology and Experimental Oncology, Klinikum rechts der Isar, Technische UniversitaÈt MuÈnchen, a1111111111 MuÈnchen, Germany, 7 The Kennedy Institute of Rheumatology, University of Oxford, Oxford, United a1111111111 Kingdom, 8 Interdisciplinary Bioscience DTP, University of Oxford, Oxford, United Kingdom a1111111111 ☯ These authors contributed equally to this work. *
[email protected] (AKP);
[email protected] (AKJ) OPEN ACCESS Abstract Citation: Anand NM, Liya DH, Pradhan AK, Tayal N, The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) which is a novel Bansal A, Donakonda S, et al. (2021) A comprehensive SARS-CoV-2 genomic analysis human coronavirus strain (HCoV) was initially reported in December 2019 in Wuhan City, identifies potential targets for drug repurposing. China. This acute infection caused pneumonia-like symptoms and other respiratory tract ill- PLoS ONE 16(3): e0248553. https://doi.org/ ness. Its higher transmission and infection rate has successfully enabled it to have a global 10.1371/journal.pone.0248553 spread over a matter of small time.